Mesenchymal Nonmeningothelial Tumors of the CNS: Evolving Molecular Landscape and Implications for Neuroradiologists

References

1. 1.↵
   1. Louis DN,
   2. Perry A,
   3. Wesseling P, et al

   . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
2. 2.↵
   1. Rigsby R,
   2. Brahmbhatt P,
   3. Desai A, et al

   . Newly recognized CNS tumors in the 2021 World Health Organization classification: imaging overview with histopathologic and genetic correlation. AJNR Am J Neuroradiol 2023;44:367–80 doi:10.3174/ajnr.A7827 pmid:36997287

   Abstract/FREE Full Text
3. 3.↵
   WHO Classification of Tumours Editorial Board. Central nervous system tumours. In: WHO Classification of Tumours Series. 5th ed; vol 20. Lyon (France): International Agency for Research on Cancer; 2021
4. 4.↵
   1. Meredith DM,
   2. Alexandrescu S

   . Embryonal and non-meningothelial mesenchymal tumors of the central nervous system—advances in diagnosis and prognostication. Brain Pathol 2022;32:e13059 doi:10.1111/bpa.13059 pmid:35266242

   CrossRefPubMed
5. 5.↵
   1. Tauziède-Espariat A,
   2. Hasty L,
   3. Métais A, et al

   . Mesenchymal non-meningothelial tumors of the central nervous system: a literature review and diagnostic update of novelties and emerging entities. Acta Neuropathol Commun 2023;11:22 doi:10.1186/s40478-023-01522-z pmid:36737790

   CrossRefPubMed
6. 6.↵
   1. d’Amati A,
   2. Gianno F,
   3. Scuccimarri L, et al

   . Intracranial mesenchymal tumor with (novel) COX14::PTEN rearrangement. Acta Neuropathol Commun 2023;11:95 doi:10.1186/s40478-023-01596-9 pmid:37312212

   CrossRefPubMed
7. 7.↵
   1. Yuzawa S,
   2. Nishihara H,
   3. Wang L, et al

   . Analysis of NAB2-STAT6 gene fusion in 17 cases of meningeal solitary fibrous tumor/hemangiopericytoma: review of the literature. Am J Surg Pathol 2016;40:1031–40 doi:10.1097/PAS.0000000000000625 pmid:26927892

   CrossRefPubMed
8. 8.↵
   1. Park HK,
   2. Yu DB,
   3. Sung M, et al

   . Molecular changes in solitary fibrous tumor progression. J Mol Med (Berl) 2019;97:1413–25 doi:10.1007/s00109-019-01815-8 pmid:31321477

   CrossRefPubMed
9. 9.↵
   1. Ohsaka T,
   2. Kojita Y,
   3. Urase A, et al

   . Solitary fibrous tumor with an acute subdural hematoma: a case report and review of the literature. Cureus 2024;16:e58271 doi:10.7759/cureus.58271 pmid:38752105

   CrossRefPubMed
10. 10.↵
    1. Fu J,
    2. Zhang R,
    3. Zhang H, et al

    . Epithelioid solitary fibrous tumor of the central nervous system. Clin Neurol Neurosurg 2012;114:72–76 doi:10.1016/j.clineuro.2011.07.021 pmid:21908099

    CrossRefPubMed
11. 11.↵
    1. Yamashita D,
    2. Suehiro S,
    3. Kohno S, et al

    . Intracranial anaplastic solitary fibrous tumor/hemangiopericytoma: immunohistochemical markers for definitive diagnosis. Neurosurg Rev 2021;44:1591–600 doi:10.1007/s10143-020-01348-6 pmid:32671693

    CrossRefPubMed
12. 12.↵
    1. Geramizadeh B,
    2. Marzban M,
    3. Churg A

    . Role of immunohistochemistry in the diagnosis of solitary fibrous tumor, a review. Iran J Pathol 2016;11:195–203 pmid:27799967

    PubMed
13. 13.↵
    1. Yue X,
    2. Huang J,
    3. Zhu Y, et al

    . Solitary fibrous tumor/hemangiopericytoma in the cerebellopontine angle mimicking vestibular schwannoma: a case report and literature review. Medicine (Baltimore) 2020;99:e19651 doi:10.1097/MD.0000000000019651 pmid:32221091

    CrossRefPubMed
14. 14.↵
    1. Chikasue T,
    2. Uchiyama Y,
    3. Tanoue S, et al

    . Intracranial solitary fibrous tumor/hemangiopericytoma mimicking cystic meningioma: a case report and literature review. Radiology Case Rep 2021;16:1637–42 doi:10.1016/j.radcr.2021.04.008 pmid:34007374

    CrossRefPubMed
15. 15.↵
    1. Sardaro A,
    2. Mammucci P,
    3. Pisani AR, et al

    . Intracranial solitary fibrous tumor: a “new” challenge for PET radiopharmaceuticals. J Clin Med 2022;11:4746 doi:10.3390/jcm11164746

    CrossRefPubMed
16. 16.↵
    1. Lopez‐Nunez O,
    2. Cafferata B,
    3. Santi M, et al

    . The spectrum of rare central nervous system (CNS) tumors with EWSR1‐non‐ETS fusions: experience from three pediatric institutions with review of the literature. Brain Pathol 2021;31:70–83.doi:10.1111/bpa.12900 pmid:32997853

    CrossRefPubMed
17. 17.↵
    1. Tauziede-Espariat A,
    2. Macagno N,
    3. Pissaloux D, et al

    . A potential diagnostic pitfall: primary synovial sarcoma of the central nervous system. Free Neuropathol 2022;3:3–11 doi:10.17879/freeneuropathology-2022-3811

    CrossRefPubMed
18. 18.↵
    1. Fritchie K,
    2. Jensch K,
    3. Moskalev EA, et al

    . The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathol 2019;137:307–19 doi:10.1007/s00401-018-1952-6 pmid:30584643

    CrossRefPubMed
19. 19.↵
    1. Macagno N,
    2. Vogels R,
    3. Appay R

    ; Dutch CNS SFT/HPC Consortium, et al. Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients. Brain Pathol 2019;29:18–27 doi:10.1111/bpa.12613 pmid:29600523

    CrossRefPubMed
20. 20.↵
    1. Lee JH,
    2. Jeon SH,
    3. Park CK, et al

    . The role of postoperative radiotherapy in intracranial solitary fibrous tumor/hemangiopericytoma: a multi-institutional retrospective study (KROG 18-11). Cancer Res Treat 2022;54:65–74 doi:10.4143/crt.2021.142 pmid:33781051

    CrossRefPubMed
21. 21.↵
    1. Liu J,
    2. Wu S,
    3. Zhao K, et al

    . Clinical features, management, and prognostic factors of intracranial solitary fibrous tumor. Front Oncol 2022;12:915273 doi:10.3389/fonc.2022.915273 pmid:35712477

    CrossRefPubMed
22. 22.↵
    1. Liang Y,
    2. Heller RS,
    3. Wu JK, et al

    . High p16 expression is associated with malignancy and shorter disease-free survival time in solitary fibrous tumor/hemangiopericytoma. J Neurol Surg B Skull Base 2019;80:232–38 doi:10.1055/s-0038-1669419 pmid:31143564

    CrossRefPubMed
23. 23.↵
    1. Ratneswaren T,
    2. Hogg FRA,
    3. Gallagher MJ, et al

    . Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease. J Neurooncol 2018;138:447–67 doi:10.1007/s11060-018-2836-2 pmid:29551003

    CrossRefPubMed
24. 24.↵
    1. Zhou L,
    2. Pan W,
    3. Huang R, et al

    . Intracranial inflammatory myofibroblastic tumor: a literature review and a rare case misdiagnosed as acoustic neuroma. Diagnostics 2023;13:2725 doi:10.3390/diagnostics13172725

    CrossRefPubMed
25. 25.↵
    1. Chanthong S,
    2. Sathitsamitphong L,
    3. Natesirinilkul R, et al

    . Treatment modalities of ALK-positive relapsed/refractory inflammatory myofibroblastic tumor of the brain and lungs in 7-year-old girl: case-based reviews. Childs Nerv Syst 2023;39:331–42 doi:10.1007/s00381-022-05789-w pmid:36515740

    CrossRefPubMed
26. 26.↵
    1. Wang G,
    2. Shen H,
    3. Chu Z, et al

    . Intracranial inflammatory myofibroblastic tumor: a report of two cases. Br J Neurosurg 2023;37:1349–53 doi:10.1080/02688697.2021.1879011 pmid:33517794

    CrossRefPubMed
27. 27.↵
    1. Vidrine DW,
    2. Berry JF,
    3. Garbuzov A, et al

    . DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS. Childs Nerv Syst 2021;37:2147–51 doi:10.1007/s00381-021-05219-3 pmid:34014367

    CrossRefPubMed
28. 28.↵
    1. Torre M,
    2. Vasudevaraja V,
    3. Serrano J, et al

    . Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun 2020;8:107 doi:10.1186/s40478-020-00980-z pmid:32665022

    CrossRefPubMed
29. 29.↵
    1. Kao YC,
    2. Sung YS,
    3. Zhang L, et al

    . EWSR1 fusions with creb family transcription factors define a novel myxoid mesenchymal tumor with predilection for intracranial location. Am J Surg Pathol 2017;41:482–90 doi:10.1097/PAS.0000000000000788 pmid:28009602

    CrossRefPubMed
30. 30.↵
    1. Bale TA,
    2. Oviedo A,
    3. Kozakewich H, et al

    . Intracranial myxoid mesenchymal tumors with EWSR1-CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity? Brain Pathol 2018;28:183–91 doi:10.1111/bpa.12504 pmid:28281318

    CrossRefPubMed
31. 31.↵
    1. Sciot R,
    2. Jacobs S,
    3. Calenbergh FV, et al

    . Primary myxoid mesenchymal tumour with intracranial location: report of a case with a EWSR1-ATF1 fusion. Histopathology 2018;72:880–83 doi:10.1111/his.13437 pmid:29143432

    CrossRefPubMed
32. 32.↵
    1. Konstantinidis A,
    2. Cheesman E,
    3. O’Sullivan J, et al

    . Intracranial angiomatoid fibrous histiocytoma with EWSR1-CREB family fusions: a report of 2 pediatric cases. World Neurosurg 2019;126:113–19 doi:10.1016/j.wneu.2019.02.107 pmid:30831299

    CrossRefPubMed
33. 33.↵
    1. Gareton A,
    2. Pierron G,
    3. Mokhtari K, et al

    . ESWR1-CREM fusion in an intracranial myxoid angiomatoid fibrous histiocytoma-like tumor: a case report and literature review. J Neuropathol Exp Neurol 2018;77:537–41 doi:10.1093/jnen/nly039 pmid:29788195

    CrossRefPubMed
34. 34.↵
    1. Sloan EA,
    2. Chiang J,
    3. Villanueva-Meyer JE, et al

    . Intracranial mesenchymal tumor with FET-CREB fusion–a unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasms. Brain Pathol 2021;31:e12918 doi:10.1111/bpa.12918 pmid:33141488

    CrossRefPubMed
35. 35.↵
    1. Mezzacappa FM,
    2. Smith FK,
    3. Zhang W, et al

    . Potential prognostic determinants for FET::CREB fusion-positive intracranial mesenchymal tumor. Acta Neuropathol Commun 2024;12:17 doi:10.1186/s40478-024-01721-2 pmid:38291529

    CrossRefPubMed
36. 36.↵
    1. Osborn A,
    2. Louis D,
    3. Poussaint T, et al

    . The 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know. AJNR Am J Neuroradiol 2022;43:928–37 doi:10.3174/ajnr.A7462 pmid:35710121

    Abstract/FREE Full Text
37. 37.↵
    1. Ding J,
    2. Zhou G,
    3. Dong Y, et al

    . Angiomatoid fibrous histiocytoma in the spinal canal of T3-T4: a case report and literature review. Br J Neurosurg 2023;37:1069–73 doi:10.1080/02688697.2020.1854686 pmid:33284054

    CrossRefPubMed
38. 38.↵
    1. Spatz M,
    2. Nussbaum ES,
    3. Lyons L, et al

    . Primary intracranial angiomatoid fibrous histiocytoma: a case report and literature review. Br J Neurosurg 2021;35:233–35 doi:10.1080/02688697.2018.1451823 pmid:29540076

    CrossRefPubMed
39. 39.↵
    1. Alshareef MA,
    2. Almadidy Z,
    3. Baker T, et al

    . Intracranial angiomatoid fibrous histiocytoma: case report and literature review. World Neurosurg 2016;96:403–09 doi:10.1016/j.wneu.2016.09.059 pmid:27667574

    CrossRefPubMed
40. 40.↵
    1. Kim NR,
    2. Kim SI,
    3. Park JW, et al

    . Brain parenchymal angiomatoid fibrous histiocytoma and spinal myxoid mesenchymal tumor with FET:CREB fusion, a spectrum of the same tumor type. Neuropathology 2022;42:257–68 doi:10.1111/neup.12814 pmid:35730186

    CrossRefPubMed
41. 41.↵
    1. Ozkizilkaya HI,
    2. Johnson JM,
    3. O’Brien BJ, et al

    . Intracranial mesenchymal tumor, FET:: CREB fusion-positive in the lateral ventricle. Neurooncol Adv 2023;5:vdad026 doi:10.1093/noajnl/vdad026 pmid:37051329

    CrossRefPubMed
42. 42.↵
    1. Tauziède-Espariat A,
    2. Sievers P,
    3. Larousserie F

    ; RENOCLIP-LOC, et al. An integrative histopathological and epigenetic characterization of primary intracranial mesenchymal tumors, FET: CREB-fused broadening the spectrum of tumor entities in comparison with their soft tissue counterparts. Brain Pathol 2022;32:e13010 doi:10.1111/bpa.13010 pmid:34314078

    CrossRefPubMed
43. 43.↵
    1. Sbaraglia M,
    2. Righi A,
    3. Gambarotti M, et al

    . Ewing sarcoma and Ewing-like tumors. Virchows Arch 2020;476:109–19 doi:10.1007/s00428-019-02720-8 pmid:31802230

    CrossRefPubMed
44. 44.↵
    1. Stacchiotti S,
    2. Frezza AM,
    3. Blay JY, et al

    . Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer 2021;127:2934–42 doi:10.1002/cncr.33618 pmid:33910263

    CrossRefPubMed
45. 45.↵
    1. Donahue JE,
    2. Yakirevich E,
    3. Zhong S, et al

    . Primary spinal epidural CIC-DUX4 undifferentiated sarcoma in a child. Pediatr Dev Pathol 2018;21:411–17 doi:10.1177/1093526617707856 pmid:28474974

    CrossRefPubMed
46. 46.↵
    1. Song K,
    2. Huang Y,
    3. Xia CD, et al

    . A case of CIC-rearranged sarcoma with CIC-LEUTX gene fusion in spinal cord. Neuropathology 2022;42:555–62 doi:10.1111/neup.12850 pmid:35859319

    CrossRefPubMed
47. 47.↵
    1. Rekhi B,
    2. Rumdee R,
    3. Shetty O

    . Clinicopathological features of five cases of CIC::DUX4 positive sarcomas, including literature review. Ann Diagn Pathol 2023;65:152153 doi:10.1016/j.anndiagpath.2023.152153 pmid:37167753

    CrossRefPubMed
48. 48.↵
    1. Song MJ,
    2. Cho KJ,
    3. Kim TI, et al

    . Distinct histologic and genetic characteristics of round cell sarcoma with CIC-DUX4 fusion and comparison with Ewing sarcoma. Pathol Res Pract 2022;231:153779 doi:10.1016/j.prp.2022.153779 pmid:35151033

    CrossRefPubMed
49. 49.↵
    1. Kallen ME,
    2. Hornick JL

    . The 2020 WHO Classification: what’s new in soft tissue tumor pathology? Am J Surg Pathol 2021;45:e1–e23 doi:10.1097/PAS.0000000000001552 pmid:32796172

    CrossRefPubMed
50. 50.↵
    1. Le Loarer F,
    2. Pissaloux D,
    3. Watson S, et al

    . Clinicopathologic features of CIC-NUTM1 sarcomas, a new molecular variant of the family of CIC-fused sarcomas. Am J Surg Pathol 2019;43:268–76 doi:10.1097/PAS.0000000000001187 pmid:30407212

    CrossRefPubMed
51. 51.↵
    1. Miele E,
    2. De Vito R,
    3. Ciolfi A, et al

    . DNA methylation profiling for diagnosing undifferentiated sarcoma with capicua transcriptional receptor (CIC) alterations. Int J Mol Sci 2020;21:1818 doi:10.3390/ijms21051818

    CrossRefPubMed
52. 52.↵
    1. Brady EJ,
    2. Hameed M,
    3. Tap WD, et al

    . Imaging features and clinical course of undifferentiated round cell sarcomas with CIC-DUX4 and BCOR-CCNB3 translocations. Skeletal Radiology 2021;50:521–29 doi:10.1007/s00256-020-03589-4 pmid:32840647

    CrossRefPubMed
53. 53.↵
    1. Yoshida A,
    2. Goto K,
    3. Kodaira M, et al

    . CIC-rearranged sarcomas: a study of 20 cases and comparisons with Ewing sarcomas. Am J Surg Pathol 2016;40:313–23 doi:10.1097/PAS.0000000000000570 pmid:26685084

    CrossRefPubMed
54. 54.↵
    1. Connolly EA,
    2. Bhadri VA,
    3. Wake J, et al

    . Systemic treatments and outcomes in CIC‐rearranged sarcoma: a national multi‐centre clinicopathological series and literature review. Cancer Med 2022;11:1805–16 doi:10.1002/cam4.4580 pmid:35178869

    CrossRefPubMed
55. 55.↵
    1. Koelsche C,
    2. Mynarek M,
    3. Schrimpf D, et al

    . Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathol 2018;136:327–37 doi:10.1007/s00401-018-1871-6 pmid:29881993

    CrossRefPubMed
56. 56.↵
    1. Lee JC,
    2. Villanueva-Meyer JE,
    3. Ferris SP, et al

    . Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathol 2019;137:521–25 doi:10.1007/s00401-019-01960-x pmid:30649606

    CrossRefPubMed
57. 57.↵
    1. Sakaguchi M,
    2. Nakano Y,
    3. Honda-Kitahara M, et al

    . Two cases of primary supratentorial intracranial rhabdomyosarcoma with DICER1 mutation which may belong to a “spindle cell sarcoma with rhabdomyosarcoma-like feature, DICER1 mutant.” Brain Tumor Pathol 2019;36:174–82 doi:10.1007/s10014-019-00352-z pmid:31487013

    CrossRefPubMed
58. 58.↵
    1. Warren M,
    2. Hiemenz MC,
    3. Schmidt R, et al

    . Expanding the spectrum of dicer1-associated sarcomas. Mod Pathol 2020;33:164–74 doi:10.1038/s41379-019-0366-x pmid:31537896

    CrossRefPubMed
59. 59.↵
    1. Kamihara J,
    2. Paulson V,
    3. Breen MA, et al

    . DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol 2020;33:1910–21 doi:10.1038/s41379-020-0516-1 pmid:32291395

    CrossRefPubMed
60. 60.↵
    1. Wolf T,
    2. Coca AH,
    3. Weingertner N, et al

    . All pineal tumors expressing germ cell tumor markers are not necessarily germ cell tumors: histopathological and molecular study of a midline primary intracranial sarcoma DICER1-mutant. Virchows Arch 2023;482:431–35 doi:10.1007/s00428-022-03440-2 pmid:36307659

    CrossRefPubMed
61. 61.↵
    1. Diaz Coronado RY,
    2. Mynarek M,
    3. Koelsche C, et al

    . Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer 2022;128:697–707 doi:10.1002/cncr.33977 pmid:34674226

    CrossRefPubMed
62. 62.↵
    1. Cardona AF,
    2. Chamorro Ortiz DF,
    3. Ruíz-Patiño A, et al

    . DICER1-associated central nervous system sarcoma: a comprehensive clinical and genomic characterization of case series of young adult patients. Neurooncol Pract 2023;10:381–90 doi:10.1093/nop/npad014 pmid:37457227

    CrossRefPubMed
63. 63.↵
    1. McCluggage WG,
    2. Foulkes WD

    . DICER1-associated sarcomas: towards a unified nomenclature. Mod Pathol 2021;34:1226–28 doi:10.1038/s41379-020-0602-4 pmid:32572152

    CrossRefPubMed
64. 64.↵
    1. Wu MK,
    2. Vujanic GM,
    3. Fahiminiya S, et al

    . Anaplastic sarcomas of the kidney are characterized by DICER1 mutations. Mod Pathol 2018;31:169–78 doi:10.1038/modpathol.2017.100 pmid:28862265

    CrossRefPubMed
65. 65.↵
    1. de Kock L,
    2. Geoffrion D,
    3. Rivera B, et al

    . Multiple DICER1-related tumors in a child with a large interstitial 14q32 deletion. Genes Chromosomes Cancer 2018;57:223–30 doi:10.1002/gcc.22523 pmid:29315962

    CrossRefPubMed
66. 66.↵
    1. Alexandrescu S,
    2. Meredith DM,
    3. Lidov HG, et al

    . Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin‐like enhancer 1 in primary intracranial sarcoma, DICER1‐mutant. Histopathology 2021;78:265–75 doi:10.1111/his.14217 pmid:32692439

    CrossRefPubMed
67. 67.↵
    1. Nejo T,
    2. Takayanagi S,
    3. Tanaka S, et al

    . Primary intracranial spindle cell sarcoma, DICER1-mutant, with MDM2 amplification diagnosed on the basis of extensive molecular profiling. Clin Med Insights Case Rep 2022;15:11795476221131189 doi:10.1177/11795476221131189 pmid:36277904

    CrossRefPubMed
68. 68.↵
    WHO Classification of Tumours Editorial Board. Digestive system tumours. In: WHO Classification of Tumours Series. 5th ed. Lyon (France): International Agency for Research on Cancer; 2019:635
69. 69.↵
    1. Raghavan SS,
    2. Mooney KL,
    3. Folpe AL, et al

    . OLIG2 is a marker of the fusion protein-driven neurodevelopmental transcriptional signature in alveolar rhabdomyosarcoma. Hum Pathol 2019;91:77–85 doi:10.1016/j.humpath.2019.07.003 pmid:31299267

    CrossRefPubMed
70. 70.↵
    1. Xie L,
    2. Wang W,
    3. Zhou H, et al

    . Adult primary pineal alveolar rhabdomyosarcoma with FOXO1 gene rearrangement and OLIG2 expression: a rare case report and literature review. Int J Surg Pathol 2022;30:769–75 doi:10.1177/10668969221080076 pmid:35188829

    CrossRefPubMed
71. 71.↵
    1. Al Mahmasani L,
    2. Najjar M,
    3. Hourany R, et al

    . Primary alveolar rhabdomyosarcoma of the brain: a case report. J Med Case Rep 2024;18:178 doi:10.1186/s13256-024-04471-w pmid:38520005

    CrossRefPubMed
72. 72.↵
    1. Tanaka R,
    2. Inoue K,
    3. Yamada Y, et al

    . A case of primary CNS embryonal rhabdomyosarcoma with PAX3-NCOA2 fusion and systematic meta-review. J Neurooncol 2021;154:247–56 doi:10.1007/s11060-021-03823-6 pmid:34398431

    CrossRefPubMed
73. 73.↵
    1. Zheng JJ,
    2. Zhang GJ,
    3. Huo XL, et al

    . Treatment strategy and long-term outcomes of primary intracranial rhabdomyosarcoma: a single-institution experience and systematic review. J Neurosurg 2020;133:1302–12 doi:10.3171/2019.6.JNS19752 pmid:31518985

    CrossRefPubMed
74. 74.↵
    1. Lau SK,
    2. Cykowski MD,
    3. Desai S, et al

    . Primary rhabdomyosarcoma of the pineal gland. Am J Clin Pathol 2015;143:728–33 doi:10.1309/AJCP9ZON4ZIHODIG pmid:25873508

    CrossRefPubMed
75. 75.↵
    1. Jour G,
    2. Serrano J,
    3. Koelsche C, et al

    . Primary CNS alveolar rhabdomyosarcoma: importance of epigenetic and transcriptomic assays for accurate diagnosis. J Neuropathol Exp Neurol 2019;78:1073–75 doi:10.1093/jnen/nlz083 pmid:31553442

    CrossRefPubMed
76. 76.↵
    1. Nishikawa M,
    2. Inoue A,
    3. Moritani K, et al

    . An extremely rare case of primary alveolar rhabdomyosarcoma in the central nervous system. Surg Neurol Int 2024;15:221 doi:10.25259/SNI_299_2024 pmid:38974556

    CrossRefPubMed
77. 77.↵
    1. Evans DGR,
    2. Salvador H,
    3. Chang VY, et al

    . Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res 2017;23:e46–e53 doi:10.1158/1078-0432.CCR-17-0589 pmid:28620004

    Abstract/FREE Full Text
78. 78.↵
    1. Filippidis A,
    2. Lidov H,
    3. Al-Ibraheemi A, et al

    . Intracranial venous malformation masquerading as a meningioma in PI3KCA-related overgrowth spectrum disorder. Am J Med Genet A 2022;188:907–10 doi:10.1002/ajmg.a.62570 pmid:34854542

    CrossRefPubMed
79. 79.↵
    1. Zafar A,
    2. Quadri SA,
    3. Farooqui M, et al

    . Familial cerebral cavernous malformations. Stroke 2019;50:1294–301 doi:10.1161/STROKEAHA.118.022314 pmid:30909834

    CrossRefPubMed
80. 80.↵
    1. Akers A,
    2. Salman RA-S,
    3. Awad IA, et al

    . Synopsis of guidelines for the clinical management of cerebral cavernous malformations: consensus recommendations based on systematic literature review by the angioma alliance scientific advisory board clinical experts panel. Neurosurgery 2017;80:665–80 doi:10.1093/neuros/nyx091 pmid:28387823

    CrossRefPubMed
81. 81.↵
    1. Adam MP,
    2. Ardinger HH,
    3. Pagon RA, et al.

    1. Morrison L,
    2. Akers A

    . Cerebral cavernous malformation, familial. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. Genereviews [internet]. Seattle: University of Washington, Seattle; 2016.
82. 82.↵
    1. Zeineddine HA,
    2. Girard R,
    3. Cao Y, et al

    . Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage. J Magn Reson Imaging 2018;47:1133–38 doi:10.1002/jmri.25831 pmid:28791783

    CrossRefPubMed
83. 83.↵
    1. Kim SJW,
    2. Lupo JM,
    3. Chen Y, et al

    . A feasibility study for quantitative assessment of cerebrovascular malformations using flutriciclamide ([(18)F]GE-180) PET/MRI. Front Med (Lausanne) 2023;10:1091463 doi:10.3389/fmed.2023.1091463 pmid:37089589

    CrossRefPubMed
84. 84.↵
    1. Morrison L,
    2. Gutierrez J,
    3. Ayata C, et al

    . Current and future treatment options for cerebral cavernous malformations. SVIN 2024;4:e001140 doi:10.1161/SVIN.123.001140

    CrossRef
85. 85.↵
    1. Peterson K,
    2. Coffman S,
    3. Zehri A, et al

    . Somatic mosaicism in the pathogenesis of de novo cerebral arteriovenous malformations: a paradigm shift implicating the RAS-MAPK signaling cascade. Cerebrovasc Dis 2021;50:231–38 doi:10.1159/000512800 pmid:33556951

    CrossRefPubMed
86. 86.↵
    1. Can A,
    2. Gross BA,
    3. Du R

    . The natural history of cerebral arteriovenous malformations. Handb Clin Neurol 2017;143:15–24 doi:10.1016/B978-0-444-63640-9.00002-3 pmid:28552137

    CrossRefPubMed
87. 87.↵
    1. Goss JA,
    2. Huang AY,
    3. Smith E, et al

    . Somatic mutations in intracranial arteriovenous malformations. PLoS One 2019;14:e0226852 doi:10.1371/journal.pone.0226852 pmid:31891627

    CrossRefPubMed
88. 88.↵
    1. Zafar A,
    2. Fiani B,
    3. Hadi H, et al

    . Cerebral vascular malformations and their imaging modalities. Neurol Sci 2020;41:2407–21 doi:10.1007/s10072-020-04415-4 pmid:32335778

    CrossRefPubMed
89. 89.↵
    1. Nguyen HS,
    2. Doan NB,
    3. Gelsomino M, et al

    . Intracranial hemangioblastoma–A SEER-based analysis 2004–2013. Oncotarget 2018;9:28009–15 doi:10.18632/oncotarget.25534 pmid:29963258

    CrossRefPubMed
90. 90.↵
    1. Simsek O,
    2. Sheth N,
    3. Manteghinejad A, et al

    . Arterial spin-labeling perfusion lightbulb sign: an imaging biomarker of pediatric posterior fossa hemangioblastoma. AJNR Am J Neuroradiol Epub ahead of print October 17, 2024 doi:10.3174/ajnr.A8391 pmid:38914433

    Abstract/FREE Full Text
91. 91.↵
    1. Tauziède-Espariat A,
    2. Pierre T,
    3. Wassef M

    ; RENOCLIP-LOC, et al. The dural angioleiomyoma harbors frequent GJA4 mutation and a distinct DNA methylation profile. Acta Neuropathol Commun 2022;10:81 doi:10.1186/s40478-022-01384-x pmid:35642047

    CrossRefPubMed
92. 92.↵
    1. Ivren M,
    2. Cherkezov A,
    3. Reuss D, et al

    . Intracranial angioleiomyoma: a case series of seven patients and review of the literature. J Neurooncol 2024;169:399–408 doi:10.1007/s11060-024-04734-y pmid:38842695

    CrossRefPubMed
93. 93.↵
    1. Leclerc T,
    2. Oppenheim C,
    3. Tauziède-Espariat A, et al

    . Teaching video neuroimage: dural angioleiomyoma: insights from dynamic imaging. Neurology 2023;101:e1835–e1836 doi:10.1212/WNL.0000000000207761 pmid:37580168

    CrossRefPubMed
94. 94.↵
    1. Sun L,
    2. Zhu Y,
    3. Wang H

    . Angioleiomyoma, a rare intracranial tumor: 3 case report and a literature review. World J Surg Oncol 2014;12:216–17 doi:10.1186/1477-7819-12-216 pmid:25027207

    CrossRefPubMed
95. 95.↵
    1. Tauziède‐Espariat A,
    2. Duchesne M,
    3. Baud J, et al

    . NTRK‐rearranged spindle cell neoplasms are ubiquitous tumours of myofibroblastic lineage with a distinct methylation class. Histopathology 2023;82:596–607 doi:10.1111/his.14842 pmid:36413100

    CrossRefPubMed
96. 96.↵
    1. Kang J,
    2. Park JW,
    3. Won J-K, et al

    . Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors. Diagn Pathol 2020;15:114–11 doi:10.1186/s13000-020-01031-w pmid:32957984

    CrossRefPubMed
97. 97.↵
    1. Gong H,
    2. Gao K,
    3. Mao P, et al

    . A rare case of spindle cell neoplasm with NTRK-fusion in central nervous system. Pathol Int 2023;73:52–54 doi:10.1111/pin.13260 pmid:35900013

    CrossRefPubMed